

Food and Drug Administration (FDA)
Center for Biologics and Evaluation and Research (CBER)
189th Meeting of the Vaccines and Related Biological Products
Advisory Committee (VRBPAC)
May 22, 2025



Committee Discussion Topic

Based on the evidence presented, please discuss considerations for the selection of JN.1 and/or a specific JN.1-lineage strain for COVID-19 vaccines (2025-2026 Formula) to be used in the U.S.